Downloading...
Download

Healthsector

Elevance Health | ELV | Long at $286.00What are seeing in the healthcare and health insurance provider industry right now is destruction before a once-in-a-lifetime boom. The baby boomer generation is between 60 and 79 right now and the amount of healthcare service that will be needed to serve that population is staggering. Institutions are crushing them to get in - it's just near-term noise, in my opinion. My personal strategy is buy and hold every healthcare opportunity (i.e. NYSE:CNC , NYSE:UNH , NYSE:HUM etc). Elevance Health NYSE:ELV just dropped heavily due to lower-than-expected Q2 2025 earnings, a cut in full-year profit guidance from $34.15-$34.85 to ~$30 EPS, and elevated medical costs in Medicaid and ACA plans. It's near-term pain (may last 1-2 years) which will highly likely lead to long-term growth. The price has touched my historical simple moving average "crash" band. I would not be shocked to see the price drop further into the $260s before a rise. However, the near-term doom could go further into the year. I am anticipating another drop to the "major crash" simple moving average band into the $190s and $220s to close out the remaining price gaps on the daily chart that occurred during the COVID crash. Not to say it will absolutely reach that area, but it's locations on the chart I have for additional buys. Thus, at $286.00, NYSE:ELV is in a personal buy zone (starter position) with more opportunities to gather shares likely near $260 before a bounce. However, if the market or healthcare industry really turns, additional buys planned for $245 and $212 for a long-term hold. Targets into 2028: $335.00 (+17.1%) $386.00 (+35.0%)
NYSE:ELVLong
by WorthlessViews
GH (Guardant Health) — Breakout Setup with Strong Upside PotentiGuardant Health (GH) is showing signs of completing a long-term accumulation phase and transitioning into a bullish trend. After breaking out of a major descending trendline and holding above key resistance at $38.30, the stock entered a tight consolidation range — a classic base formation before a potential breakout. Technical Highlights: – Confirmed trendline breakout – Price is consolidating above previous highs – Entry zone around $50–$51 – First target: $70 (+40%) – Second target: $103 (+100% from current levels) Fundamental Support: Guardant Health is a leading precision oncology company specializing in liquid biopsy technologies for cancer screening and monitoring. The company continues to expand its product offerings, especially in early cancer detection — a market with huge long-term growth potential. Recent news includes positive developments in clinical trials and expanded partnerships, which could significantly boost revenue. Institutional interest in GH has also been rising, with increased buying activity visible in the most recent 13F filings. The overall market sentiment toward biotech stocks with strong data pipelines is improving, which further supports the bullish outlook. Conclusion: GH is a strong candidate for medium- to long-term growth. The technical setup aligns with a fundamental narrative of innovation and market expansion. Partial profit-taking could be considered at $70 and $103. Due to the volatility of biotech stocks, proper risk management and position sizing are essential.
NASDAQ:GHLong
by InvestWorld_777
HIMS – Technically and Fundamentally Strong for Mid-to-Long TermTechnical Analysis HIMS is trading in a clear ascending channel since 2023. On the daily chart, a “cup and handle” formation has completed, with a confirmed breakout above the neckline ($55–$57 area). The price is consolidating near the breakout point – classic behavior before a continuation move. Target projection from the cup pattern is $170+, implying a 200%+ upside potential. The stock also respects the upper trendline of the long-term channel, reinforcing bullish structure. Fundamental Strength: Telemedicine megatrend: Digital health is booming. HIMS is one of the few well-established D2C players in the U.S. market. Revenue growth: Annual revenue growth exceeds 40% YoY, a sign of operational efficiency and demand. Sticky subscription model: Over 1.5 million active subscribers — solid base for recurring revenue and LTV. Valuation upside: Still undervalued relative to sector peers despite recent rally. Scalable tech stack: Strong backend, customer acquisition systems, and vertically integrated infrastructure support further expansion. Conclusion: HIMS offers an attractive risk–reward setup for swing traders and long-term investors alike
NYSE:HIMSLong
by InvestWorld_777
CVAC - Trade Opportunity Looking through charts, CVAC caught my eye for some potential trade opportunities. Firstly lets look at the candle close of Today 08/01/23 -> We are currently testing this RED Resistance Arrow Line pointing down -> The candle has a lower wick, indicating some buying pressure ->However, the candle body is small, which may indicate waning momentum **If price action CONFIRMS above RED ARROW -> This can be a TRADE SETUP -> If this plays out - TARGET = $10.65 or a potential 17% move -> STOP LOSS should be placed below RED ARROW Notice the GREEN circle indicating a bounce UP from 2 converging support lines -> The 200 DMA -> this is important as if we maintain support on 200 DMA, it indicates Bullish activity, price has a possibility of traveling back to UPPER BLACK RESISTANCE LINE BUT NOTE: This is the first time for CVAC to be doing this, so we have to be cautious, as FAKEOUTS are possible. -> The orange sloping support line ~~ Having 2 support lines converge makes SUPPORT two-folds stronger, which may create ncessary momentum for price to break above RED ARROW Now Notice how the ORANGE SUPPORT LINE coincides with the ORANGE line found on the RSI and MACD -> This is known as a BEARISH DIVEGENCE -> Where price shows a higher low but Indicators show lower lowers. -> This leads to PRICE DECLINES if it plays out, may lead Price Action to go towards the BLACK Support line or where the RED ARROW is pointing at. -> Its also not necessary that it plays out right away, we can technically hit my TARGET of $10.65 and then have the DIVERGENCE play out. *** Regardless of what happens, BLACK SLOPING SUPPORT LINE can be a BUY ZONE with STOP LOSS BELOW this line. This would be to catch a bounce off this line. RSI orange line MUST stay above or act as SUPPORT on the BLACK moving average, this normally leads to PRICE increasing MACD (Momentum indicator) -> must continue this histogram pattern of waning bearish momentum, we must print GREEN histogram. -> There needs to be a BULLISH CROSS where BLUE line crosses above the ORANGE line. -> This would help us breakout of the RED ARROW RESISTANCE STOCH RSI -> BLUE line has CROSSED over ORANGE, and we are ABOVE the 20 level. This indicates BULLISH MOMENTUM. -> We must continue UPWARD above the 80 level, this indicates continuation of MOMENTUM, if we keep this direction -> It may HELP us BREAKOUT of RED ARROW RESISTANCE LINE. CONCLUSION: All in all, we are in a interesting area for CVAC the stock. New things are happening in the price action, that has not been seen in the history of CVAC. 200 DMA acting as support for the 1st time, STOCH RSI Bullish cross and waning of bearish momentum in MACD can be the necessary catalyst to push PRICE above the RED ARROW RESISTANCE. If so TARGET = $10.65 or a 17% Trade. However, it is important to note the BEARISH DIVERGENCE forming, though a sign of DOWNWARD PRICE ACTION, can also lead to opportunity of a trade setup. Never fight the trend, its always better to ride along. Thanks you! Hope this helps, please support my ideas by boosting, following and commenting! Do check out my page of other trade ideas. I have linked a couple of recent ideas ive had, check em out if you'd like. DISCLAIMER: This is not Financial advice, i am NOT a Financial advisor. Thoughts expressed here are my only my opinion and for educational purposes. Do practice due diligence and focus on risk mamangement. Deploy stop losses to protect yourself. Thanks.
NASDAQ:CVAC
by SafofAllTrades
UnitedHealthGroup Analysis 19.11.2022Welcome to the BasicTrading channel. My name is Philip and in todays analysis I quickly go over the situation which we currently have on UnitedHealth Group. I will analyse the asset both from a weekly and daily timeframe to show you the best possible trading opportunities. If you enjoyed this analysis, let me know in the comment section which asset I should analyse tomorrow. I will personally reply to every single comment. Dont forget to smash that rocket and I will see you tomorrow with a new analysis.
NYSE:UNH
by basictradingtv
3
Healthcare is still in a bull market - be longAt the start of 2022, healthcare stocks have gotten killed, especially anything that was a winner in the past 1-2 years. A lot of people are getting rather bearish, but they shouldn't be. The fundamentals favor healthcare still in many ways, and momentum is still rather strong. We already got the breakout in healthcare stocks, and we just got the retest, which was enough to scare a lot of people out. Now is a great entry for a long position, coming out of a short consolidation into a potential new bull phase.
AMEX:XLVLong
by GTStockmaster
$CHEK Receives FDA IDE Approval for Pivotal Study of C-Scan®Check-Cap Receives FDA IDE Approval for Pivotal Study of C-Scan® today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational Device Exemption (IDE) application, permitting Check-Cap to begin a pivotal study of C-Scan in the U.S. The pivotal study will evaluate safety and performance of C-Scan as well as subject compliance with C-Scan. Now with IDE in hand, we aim to enter the last phase of demonstrating the clinical potential of C-Scan in the U.S., with the ultimate goal of commercialization in this important market. "We are in active discussions with a number of clinical sites as part of our preparations to begin the pivotal study in late 2021. finance.yahoo.com
NASDAQ:CHEK
by AlenCiken
$ZOM could surge 100% due to upcoming launch of TruformaTangible catalyst behind surge is due to the upcoming launch of Truforma , Zomedica’s point-of-care (POC) diagnostic device for the detection of thyroid disease in dogs and cats and adrenal disease in dogs. The platform will hit the market on March 30 , and ahead of the product’s debut, the company has also just nabbed a vital distribution deal. Last week, Zomedica announced an agreement with Miller Veterinary Supply who will distribute Truforma. Miller is the U.S.’s oldest wholesale veterinary distributor and one of the veterinary industry’s fastest growing businesses. The company will be Zomedica’s representative in the eastern and mid-eastern states. Its sales and customer service efforts will be bolstered by sales representatives assigned by Zomedica, which the company is currently recruiting as it prepares for the launch. The pet market has been a prime beneficiary of the pandemic’s stay-at-home mandates and according to the American Pet Products Association, spending in the segment reached a record $99 billion in the U.S. last year. Outlay on diagnostic care in this market is expected to grow to $2.8 billion in 2024 from $1.7 billion in 2019. H.C. Wainwright analyst Swayampakula Ramakanth says that ahead of Truforma’s debut, the agreement “strengthens the commercial machinery.” “We are encouraged by the progress in commercial preparation for the upcoming launch, and accordingly we are raising the probability of launch to 90%, up from 75% previously,” the 5-star analyst said. “Additionally, due to the lower yield of the long-term Treasury note that has resulted in a lower risk-free rate and a lower market risk premium, we have adjusted the discount rate to 6% from 12%.” To this end, Ramakanth boosted his price target on ZOM from $0.3 to $1.2, suggesting upside of an additional 20% from current levels. Needless to say, Ramakanth’s rating stays a Buy. finance.yahoo.com
Z
by AlenCiken